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Surgery is the treatment of choice for patients with non-small cell lung cancer (NSCLC)
stages I-IIIA. However, more than 20% of these patients develop recurrence and die due to
their disease. The release of tumor cells into peripheral blood (CTCs) is one of the main
causes of recurrence of cancer. The objectives of this study are to identify the prognostic
value of the presence and characterization of CTCs in peripheral blood in patients undergo-
ing radical resection for NSCLC.
Patients and Methods
56 patients who underwent radical surgery for previously untreated NSCLC were enrolled in
this prospective study. Peripheral blood samples for CTC analysis were obtained before
and one month after surgery. In addition CTCs were phenotypically characterized by epider-
mal growth factor receptor (EGFR) expression.
Results
51.8% of the patients evaluated were positive with the presence of CTCs at baseline. A
decrease in the detection rate of CTCs was observed in these patients one month after sur-
gery (32.1%) (p = 0.035). The mean number of CTCs was 3.16 per 10 ml (range 0–84) pre-
operatively and 0.66 (range 0–3) in postoperative determination. EGFR expression was
found in 89.7% of the patients at baseline and in 38.9% patients one month after surgery.
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The presence of CTCs after surgery was significantly associated with early recurrence (p =
0.018) and a shorter disease free survival (DFS) (p = .008). In multivariate analysis CTC
presence after surgery (HR = 5.750, 95% CI: 1.50–21.946, p = 0.010) and N status (HR =
0.296, 95% CI: 0.091–0.961, p = 0.043) were independent prognostic factors for DFS.
Conclusion
CTCs can be detected and characterized in patients undergoing radical resection for non-
small cell lung cancer. Their presence might be used to identify patients with increased risk
of early recurrence.
Introduction
Lung cancer represents the leading cause of cancer related death for both men and women, and
even in early stages outcomes remain poor [1]. Despite optimal surgical treatment more than
20% of patients designated as early stages by conventional criteria will recur and eventually die
of recurrent non-small cell lung cancer (NSCLC) [2,3]. This group of patients with worse than
expected prognosis makes it necessary to improve risk stratification with more sensitive prog-
nostic factors. These new prognostic factors must be the result of a better understanding of
metastatic process, intimately linked with the detection of CTCs.
In this regard increasing evidence suggests that early relapse in resected NSCLC patients
may arise from circulating tumor cells (CTCs) that shed from the primary tumor into the vas-
cular system since the beginning of the malignant process. Detection of these CTCs may iden-
tify patients with a high risk of recurrence and could be a more specific indication for adjuvant
treatment in these patients [4].
Prognostic value of CTC enumeration has been shown in several types of epithelial tumors
and a worse survival has been described in patients with a higher number of CTCs in breast,
prostate and colorectal cancer [5–8]. In lung cancer most clinical studies have focused on
CTCs detection in metastatic cancer patients as a prognostic factor and as a biomarker of
response to treatment [9]. Isolation of CTCs in early stage NSCLC is more challenging and
only a few articles can be found suggesting that CTCs numbers can help to predict prognosis
[10–13].
Recent findings about CTCs suggest that simply enumeration at a certain moment may not
be sufficient [14,15]. It has been proved that CTCs are actually a heterogeneous population and
it is known that the genetic and phenotypic characteristics of tumor cells are known to change
over time in treated patients. Therefore, not only enumeration but also CTC characterization
should be performed at different moments along the follow up. CTC characterization may con-
tribute to identify different subpopulation of CTCs with different possible implications in
patient prognosis [14]. Moreover CTC characterization could provide information about geno-
typic and phenotypic features of a tumour without the need for an invasive biopsy, for instance
the detection of epidermal growth factor receptor (EGFR) mutations in NSCLC patients [15].
Nevertheless, the existence of possible discordance between genotypes obtained by tumor
biopsy and that determined in CTCs must be taken into account. It has been described in a
recent study that relates these discordances with technological differences as well as sampling
different tumour cell populations [16].
Epithelial growth factor receptor (EGFR) has been identified in various human tumors,
including cancers of breast, ovary, oropharynx, and esophagus, and has predicted poor patient
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outcomes [17]. Mutations that lead to EGFR overexpression or overactivity have been associ-
ated with a number of cancers, including lung cancer. These somatic mutations involving
EGFR lead to its constant activation, which produces uncontrolled cell division [18].
Therefore, we are interested in exploring the presence of CTCs and to determine EGFR
expression in CTCs in patients with NSCLC. CTC detection and characterization might
become a valuable tool to determine prognosis and serve as a real-time tumor biopsy for indi-
vidually tailored cancer treatment.
In this context, we conducted this study with the following goals: (i) to determine whether
CTCs are detectable in patients undergoing radical resection for NSCLC, (ii) to phenotypically
characterize these CTCs and (iii) to assess the prognostic significance of CTC detection in
these patients in terms of recurrence and disease free survival.
Patients and Methods
Study design and patients
Given this background we conducted a prospective longitudinal cohort study of 56 patients
with NSCLC who underwent a curative resection at the Department of Thoracic Surgery, Vir-
gen de las Nieves University Hospital at Granada (Spain), between November 2012 and Janu-
ary 2014. Peripheral blood samples were collected before the operation (2–16 hours before)
and one month after surgery and were sent to GENyO Centre (Centre for Genomic and Onco-
logical Research located in Granada) for CTC analysis. Control blood samples were drawn
from 16 healthy volunteers with no history of malignant disease. Informed consent was
obtained from each patient, and the study was approved by the local ethics committee. Median
follow up for all patients was 16 months (range 3–23). Clinical outcomes were evaluated in
terms of recurrence and disease free survival. Data were collected for age, gender, smoking sta-
tus, histological subtype, SUV (standardized uptake value), value of positron emission tomog-
raphy–computed tomography (PET CT), surgical approach, extent of resection, pathological
stage, adjuvant treatment, survival, and response.
All 56 patients with NSCLC underwent anatomical pulmonary resection and systematic
lymph node dissection with curative intent. Complete resection was defined as demonstrating
cancer-free surgical margins, both grossly and histologically. None of these patients received
induction chemotherapy or radiotherapy. Another exclusion criteria was either concurrent or
prior malignancy in the previous 5 years and death within 30 days of operation. In addition,
preoperative evaluation included history, physical examination, and laboratory and radio-
graphic studies including PET CT.
The clinicopathological characteristics of these 56 patients are summarized in Table 1.
Pathologic stage was determined in accordance with the 7th edition of the international
tumor-node-metastasis (TNM) system. Histologic subtypes of lung cancer were assigned
according to the World Health Organization classification.
Indication for adjuvant treatment was established by the Local Tumor Committee according
to ASCO guidelines. In case of adjuvant treatment it was initiated after the second blood
extraction.
The follow-up schedule was the usually performed for resected NSCLC and it consisted of a
first clinical visit one month after surgery, then one every 3 months in the first year after resec-
tion and finally one every 6 months from the second to the fifth year. At least one chest CT
scan was performed every 6 months and a PET-CT study per year.
Local recurrence was defined as that occurring at the following sites: ipsilateral lung, bron-
chial stump or staple line, and regional lymph node (subcarinal, periesophageal, ipsilateral or
contralateral mediastinum, supraclavicular, or hiliar lymph nodes).
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Table 1. Main demographic, clinical, pathological and treatment related characteristics in NSCLC
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(N: Number of patients)
doi:10.1371/journal.pone.0148659.t001
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Distant recurrence included metastases in the contralateral lung, liver, adrenal glands,
brain, bone, or other locations. Patterns of recurrence were determined by clinical assessment,
radiographic test and supplementary data from bronchoscopy, biopsy, and PET.
This study was approved by the ethical Committee of the Hospital. Written informed con-
sent was obtained from all the cancer patients and healthy volunteers in this study.
Statistical Analysis
Patients were considered CTC positive if at least one CTC was isolated. CTCs were assessed
both as continuous variable and as binary variable (presence/absence). The relationships
between CTCs and other variables were ascertained by a t-test and ANOVA (comparison of
means) when CTC were continuous and Fisher's exact test when CTC were considered as a
binary variable. To compare CTCs measured at two different times the Wilcoxon signed-rank
test was used. The influence of CTC on disease-free survival was measured by univariate meth-
ods (Kaplan-Meier) and multivariate procedures (Cox regression). In the selection of variables
to be included in multivariate Cox regression, the criterion of more than a 10% change in the
CTC coefficient estimate was applied [19].
Enumeration and Characterization of CTCs by CK and EGFR
expression
A total of 20 ml of blood were collected from each donor in two Cell Save Preservatives blood
collection Tubes (Veridex, LLC, Johnson & Johnson Company) CTC detection was performed
by positive immunomagnetic selection. Samples were processed according to the protocol we
have previously established [8] (S1 Text).
Briefly, the samples were processed by density gradient centrifugation (Histopaque 1119;
Sigma-Aldrich, St. Louis, MO, USA). For CTC enrichment, we used the Carcinoma Cell
Enrichment and Detection kit with MACS technology (Miltenyi Biotec, Bergisch Gladbach,
Germany). CTCs were identified by immunocytochemical methods and visualized under a
direct light microscope to perform the combined cytomorphological and immunophenotypic
assessment. CK-positive and EGFR-positive cells were identified by immunohistochemistry
(IHC) and signals were detected by chromogenic and fluorescent detection, respectively [20]
Epithelial tumor cells were identified and enumerated based on their red staining for CK-posi-
tive cells and blue staining for EGFR-positive cells (Fig 1).
Specific staining can easily be distinguished due to the differential intracellular distribution
of the examined molecules and the combination of direct and indirect IF in order to evaluate
CK+/EGFR+.
Results
CTCs detection and correlation with clinicopathological characteristics
CTCs were detected in peripheral blood of 51.8% of patients at baseline (CTC1) (29 of 56
patients) Interestingly, we observed that the detection rate of CTCs in these patients was signif-
icantly lower one month after surgery (CTC2) (18 patients, 32.1%) p = 0.034, yielded from the
Wilcoxon signed-rank test. The mean number of CTCs was 3.16 per 10 ml (median 1; range
0–84) preoperatively and it decreased to 0.66 (median 0; range 0–3) after the operation (S1
Table) (p = 0.051). Dynamic changes in CTCs number were also determined observing that
most patients with CTCs at baseline presented a decrease in CTCs count (25 out of 29) after
surgery. On the other hand only 11 patients showed an increase.
Correlation between CTCs presence and patient characteristics is summarized in Table 2.
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Fig 1. Image galleries after isolation, cytomorphological analysis, and detection of cytokeratin-positive (CK+) cells (red staining) and epidermal
growth factor receptor (EGFR). A) T1975 cell tumor line. was used as positive control for EGFR expression B) A control in which the slides are incubated
with antibody diluent, without the primary antibody was included. (C, D) Expression of different markers in patients with non-small lung cancer through
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In the univariate analysis only the type of resection showed a significant correlation with
CTC presence after surgery (P = 0.034). 4/4 patients underwent pneumonectomy resection
changed from CTC1+ to CTC2-, while 7 of 25 who had another type of resection changed to
CTC2-. CTC count in the second detection was correlated with max SUV of PET scan (β =
0.05 95%; 95% CI 0.001–0.106, p = 0.046). In the multivariate analysis there was no significant
correlation between CTC presence or number and any clinicopathological characteristic
analysed.
Characterization of EGFR in CTCs
The CTCs were also analyzed for epidermal growth factor receptor (EGFR) expression, EGFR
expression was found in 26 patients at baseline and in 7 patients one month later. For CTC
positive cases EGFR expression rate was 89.7% before and 39% after surgery. There was no sig-
nificant correlation between CTCs EGFR+ status and clinico-pathological characteristics.
Prognostic significance of CTCs detection
During the follow up 16 patients showed evidence of cancer recurrence (28.6%). Median time
to recurrence was 8 months, ranging between 2 and 17 months after surgery. Pattern of recur-
rence was: distant 7, locoregional 4 and both 5. For the entire cohort 1-year DFS rate was
76.6%. Association between recurrence and most important prognostic factors was analyzed
(Table 3). Only CTC presence after surgery was significantly associated with early recurrence,
50% of patients with detectable CTCs after surgery (CTC2+) developed a recurrence compared
to 18.4% for CTC2 negative patients (p = 0.018). Regarding nodal extension, N1-N2 positive
patients presented a higher percentage of recurrence than N0 patientes althought the difference
was not significant (p = 0.161).
Considering only CTCs positive patients, EGFR expression in CTCs didn’t show a signifi-
cant correlation with tumor recurrence (Table 4) In the second detection 28.6% of EGFR
+CTC2+ patients presented a recurrence compared to 63.4% of EGFR-CTC2+ patients but the
difference was not siginificant (p = 0.335) (Table 4)
In addition CTC presence after surgery (CTC2) was associated with a shorter DFS, with one
year DFS rate of 51% compared to 87.7% for CTC negative group after surgery (log rank test
p = 0.008) (Fig 2). Although the mean number of CTC after surgery was greater for patients
with recurrence, the difference was not significant (1 cell per 10 ml vs 0.5 per 10 ml, p = 0.13).
The detection of CTCs after surgery was significantly correlated with a shorter DFS in
patients undergoing radical resection for Non-Small-Cell Lung Cancer.
Prognostic factors for disease-free survival were identified by the univariate Cox propor-
tional hazards regression analysis (Table 5). Factors associated with DFS that had a p 0.1
were CTC presence after surgery (CTC2) (p = 0.014) and N status (p = 0.07)
The multivariate forward stepwise Cox proportional hazards regression analysis, revealed
that CTC presence after surgery (HR,5.75; 95% CI 1.50–21.95; p = 0.01) and N status (HR,3.38;
95% CI 1.04–10.9; p = 0.043) were independent prognostic factor for DFS (Table 6).
Discussion
The clinical value of CTCs detection in patients´ blood is becoming increasingly important as
cancer biomarker research [14]. The main goal of CTC detection in early stages NSCLC is to
combination of stained CK+ cells (red) with EGFR (blue). EGFR-specific immunofluorescence (IF) of circulating tumor cells (CTCs) was determined with
Alexa 355.
doi:10.1371/journal.pone.0148659.g001
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identify patients with a high risk of recurrence after surgery in order to adopt the best strategy
for treatment and follow up.
In this prospective study we found that CTC presence after surgery is associated with early
recurrence and a shorter disease free survival in patients with surgical treatment of NSCLC
In our analysis, which enrolled 56 patients who had undergone radical surgery for previ-
ously untreated NSCLC, detection rate was significantly lower one month after surgery
(32.14% vs. 51.79% before surgery, p = 0.034).
There are only a few studies that evaluate the prognostic significance of CTCs detection in
resected NSCLC and even less that perform a second detection after surgery [10–13]. In a
study by Hofman et al. [10] including I-IV stages resectable patients, the detection rate is simi-
lar to ours (49%). They perform only one presurgery CTCs detection employing a technique
based on isolation by size (ISET technique), and they found that a CTC count of 50 cells or
more is correlated with a worse overall and disease free survival. In another small scale study
by Rolle et al. [11] 30 patients with resectable NSCLC were examined using the MAINTRAC
technique, based on cytometric assay. CTCs were determined 2 weeks and 5 months after sur-
gery. The CTCs count was compared to prognosis and patients with continuously increasing in
median CTC-count post-operatively were shown to be at a higher risk of relapse.
Only two more prospective studies [12,13] using CellSearch system to detect CTCs, have
reported so far the clinical impact of CTCs detection in peripheral blood before and after sur-
gery. However, both failed to demonstrate any difference in either survival or recurrence. Both
of them analyzed CTCs presence in blood immediately after surgery. Sawabata´s group [13]
observed that CTCs disappeared ten days after operations. In fact, it is well known that during
surgery a large number of CTCs can be shed into the blood stream but it has not been
Table 2. Correlation between CTCs status before (CTC1) and after surgery (CTC2) and clinicopathological characteristics.
CTC1 CTC2
N(%) + N(%) - p N(%) + N(%) - p
Age (years) < 70 13 (41.9%) 18 (58.1%) 0.116 11 (35.5%) 20 (64.5%) 0.58
 70 16 (64%) 9 (36%) 7 (28%) 18 (72%)
Gender Male 27 (54%) 23 (46%) 0.301 17 (34%) 33 (66%) 0.363
Female 2 (33.3%) 4 (66.7%) 1 (16.7%) 5 (83.3%)
p TNM Stage I 13 (50%) 13 (50%) 0.508 7 (26.9%) 19 (73.1%) 0.313
II-III 16 (53.3%) 14 (46.7%) 11 (36.7%) 19 (63.3%)
Nodal status N0 21 (48.8%) 22 (51.2%) 0.315 14 (32.6%) 29 (67.4%) 0.594
N1-N2 8 (61.5%) 5 (38.5%) 4 (30.8%) 9 (69.2%)
Tumor size < 3 13 (56.5%) 10 (43.5%) 0.375 7 (30.4%) 16 (69.6%) 0.527
(cm)  3 16 (48.5%) 17 (51.5%) 11 (33.3%) 22 (66.7%)
PET < 7 7 (63.6%) 4 (36.4%) 0.380 4 (36.4%) 7 (63.6%) 0.738
(max SUV value)  7 22 (48.9%) 23 (51.1%) 14 (31.1%) 31 (68.9%)
Histology Adenocarcinoma 11 (44%) 14 (56%) 0.218 8 (32%) 17 (68%) 0.606
Other 18 (58.1%) 13 (41.9%) 10 (32.3%) 21 (67.7%)
Surgical approach Thoracotomy 18 (50%) 18 (50%) 0.469 12 (33.3%) 24 (66.7%) 0.521
VATS 11 (55%) 9 (45%) 6 (30%) 14 (70%)
Type of ressection Pneumonectomy 4 (50%) 4 (50%) 0.605 0 (0%) 8 (100%) 0.034
Other 25 (52.1%) 23 (47.9%) 18 (37.5%) 30 (62.5%)
(N: Number of patients)
doi:10.1371/journal.pone.0148659.t002
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demonstrated that these cells are involved in the development of any future metastases. A
number of them are apoptotic and many of them will be eliminated by the immune system
[14]. That is why we think that for a real assessment of CTC presence after surgery the second
detection must be performed at least 3 weeks after the operation.




< 70 8 25.8% 23 74.2% 0.767
 70 8 32% 17 68%
Histological type
Adenocarcinoma 7 28% 18 72% 0.932
Other 9 29% 22 71%
PET (maxSUV value)
< 7 5 45.5% 6 54.5% 0.263
 7 11 24.4% 34 75.6%
Pathological stage
I 7 26.9% 19 73.1% 0.518
II + III 9 30% 21 70%
Tumoral size (cm)
< 3 5 21.7% 18 78.3% 0,262
 3 11 33.3% 22 66.7%
N status
N0 10 23.3% 33 76.7% 0.161
N1-N2 6 46.2% 7 53.8%
Surgical approach
Thoracotomy 10 27.8% 26 72.2% 0.547
VATS 6 30% 14 70%
Type of resection
Other 13 27.1% 35 72.9% 0.676
Pneumonectomy 3 37.5% 5 62.5%
Adjuvant chemotherapy
Yes 5 23.8% 16 76.2% 0.384
No 11 31.4% 24 68.6%
CTC 1
Yes 10 34.5% 19 65.5% 0.237
No 6 22.2% 21 77.8%
CTC 2
Yes 9 50% 9 50% 0.018
No 7 18.4% 31 81.6%
EGFR+ CTC1
Yes 9 34.6% 17 65.4% 0.262
No 7 23.3% 23 76.7%
EGFR+ CTC 2
Yes 2 28.6% 5 71.4% 0.655
No 14 28.6% 35 71.4%
doi:10.1371/journal.pone.0148659.t003
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Indeed we found a significant decrease in CTCs detection rate one month after surgery:
CTCs were not detected in peripheral blood in almost 70% of patients in the second detection,
and 25 out of 29 patients with CTCs presence at baseline showed a decrease in CTC count.
This finding can be one of the reasons that explains why surgery remains the best treatment
option in early stages.
The presence of CTCs one month after radical resection might indicate the presence of
another source of CTCs not removed by surgery, such as those undetectable by conventional
methods.
In accordance with that, in our study patients with detectable CTCs in peripheral blood one
month after surgery presented a worse prognosis. Presence of CTCs after surgery (CTC2) was
significantly associated with recurrence and DFS, so that CTC2 positive patients presented a
higher risk of recurrence (p = 0.018) and a shorter DFS. The one year DFS rate was 51% in
CTC2 positive patients compared to 87% for CTC2 negative patients (log rank test p = 0.008).
CTC level was higher in patients with recurrence but the difference was not siginificant (mean
number of 1 cell per 10 ml for patients with recurrence vs 0.5 per 10 ml for patients who did
Table 4. Recurrence according EGFR expression for CTC positive patients. EGFR1 = EGFR expres-




+ 9 34.6% 17 65.4% 26 1
- 1 33.3% 2 66.7% 3
EGFR 2
+ 2 28.6% 5 71.4% 7 0.335
- 7 63.6% 4 36.4% 11
n = number of patients.
doi:10.1371/journal.pone.0148659.t004
Fig 2. Kaplan-Meier curves of disease free survival according to CTC status before (A) and one month after surgery (B). CTC1: CTC presence before
surgery. CTC2: CTC presence after surgery.
doi:10.1371/journal.pone.0148659.g002
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not develop a recurrence, p = 0.13).The mere presence of at least one CTCs after surgery
(CTC2+) was significantly associated with patient prognosis in our analisys. Our results reflect
that the presence of post-surgery CTCs (HR,5.75; 95% CI 1.50–21.95; p = 0.01) and nodal sta-
tus (HR,3.38; 95% CI 1.04–10.9; p = 0.043) are good independent prognostic factors for DFS in
multivariate analysis.
CTCs count in post-surgical samples showed an association with the max SUV of PET scan
(p = .046). This is the first time that this association has been analysed. Max Suv value of PET
scan has been associated with a worse prognoses and it could be related to a higher risk of post-
operative CTCs presence.
Besides detection, CTCs characterization could be important to assess prognosis and the
type of adjuvant treatment or to determine the best option of treatment for recurrent disease.
EGFR expression was detected in 89.7% and 38.9% of CTCs isolated from blood samples taken
before and after surgery, respectively. Regarding the prognostic siginificance of EGFR expres-
sion we found that 28.6% of patients with EGFR+CTC2+ experienced a recurrence compared
to 63.6% for EGFR-CTC2+, but the difference was not significant. In our study CTCs detection
after surgery was associated with worse prognosis but EGFR characterization was not. Probably
a large-scale study may determine the EGFR expression influence in these patients prognosis.
Table 5. Univariate analysis of risk factors for disease-free survival (DFS).
DFS Univariate Analysis
PROGNOSTIC FACTORS HR 95% IC p
CTC 1 + 1.34 0.48–3.71 0.574
CTC 2 + 3.481 1.29–9.38 0.014
EGFR CTC 1 + 1.332 0.49–3.59 0.571
EGFR CTC 2 + 1.027 0.23–4.53 0.971
Histological type
Ohter 1.07 0.39–2.87 0.89
Adenocarcinoma
PET (max SUV value)
<7
7 0.535 0.19–1.54 0.247
Tumor size (cm)
3 1.85 0.64–5.32 0.256
<3
N status
N1-N2 2.54 0.92–7.04 0.07
N0
Surgical approach
VATS 1.21 0.44–3.34 0.712
Thoractomy
Type of resection
Pneumonectomy 1.18 0.34–4.15 0.794
Other
Adjuvant chemotherapy
Yes 0.63 0.22–1.82 0.392
No
HR = Hazard ratio; CI = confidential interval; CTC = circulating tumor cells
doi:10.1371/journal.pone.0148659.t005
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On the other hand, it is worth stressing that current methodologies allow us to detect only
the subpopulation of CTCs positive for epithelial markers, but not subpopulations positive for
expression of mesenchymal markers and with a semi mesenchymal or mesenchymal pheno-
type. These phenotypes have been correlated with bad prognosis in different type of tumors
[21] and therefore they should be analysed in future studies in order to achieve a better under-
standing of the prognostic role of CTCs in lung cancer.
To our knowledge, this study is the first large data set to validate CTCs as a prognostic
marker performing postsurgery detection and to assess not only the risk of early recurrence but
also to determine CTCs as predictive markers through their characterization.
In conclusion, our results show that CTCs can be detected in the blood of patients undergo-
ing radical surgery for NSCLC. CTC detection after surgery could be an important prognostic
marker contributing to risk stratification by identifying patients with a higher risk of early
recurrence. Further studies are warranted to validate these results.
Supporting Information
S1 Table. CTCs recovery rate in lung cancer patients.
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Table 6. Multivariate analysis of risk factors for disease-free survival (DFS).
Multivariate Analysis DFS
PROGNOSTIC FACTORS HR 95% CI p
CTC 2 + 5.750 1.50–21.95 0.010
Tumor size (cm)
3 3.10 0.72–13.42 0.129
<3
N status
N1-N2 3.38 1.04–10.99 0.043
N0
Surgical approach
VATS 4.11 0.81–20.85 0.088
Thoractomy
Type of resection
Pneumonectomy 3.92 0.61–25.01 0.149
Lobectomy/segmentectomy
Adjuvant chemotherapy
Yes 0.44 0.10–1.82 0.256
No
HR = Hazard ratio; CI = confidential interval; CTC = circulating tumor cells
doi:10.1371/journal.pone.0148659.t006
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